Progress in Cancer Drug Resistance Research

Parsons, Robert A. (EDT); Altamirano, Natalia A. (CON); An, Ran (CON); Bernardini, Sergio (CON); Chan, Marion M. (CON)

ISBN 10: 1600218229 / ISBN 13: 9781600218224

Edité par Nova Science Pub Inc, 2007

A propos de cet article

Unread book in perfect condition.

N° de réf. du vendeur 5448435

Détails bibliographiques

• Titre: Progress in Cancer Drug Resistance Research
• Éditeur: Nova Science Pub Inc
• Date de parution: 2007
• Langue: anglais
• ISBN à 10 chiffres: 1600218229
• ISBN à 13 chiffres: 9781600218224
• Reliure: Couverture rigide
• État de l'article: As New

A propos de ce titre

Synopsis

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common. The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anti-cancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information on how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.